Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Acetanilide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.73 |
| ▸ | CACNA1B known ✓ | Q00975 | 1/20 | 0.64 |
| ▸ | CA2 known ✓ | P00918 | 1/20 | 0.60 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.95 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.95 |
| ▸ | MAPT | P10636 | 4/20 | 0.79 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.79 |
| ▸ | NPC1 | O15118 | 2/20 | 0.79 |
| ▸ | RAB9A | P51151 | 2/20 | 0.79 |
| ▸ | POLB | P06746 | 2/20 | 0.79 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.79 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.67 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.64 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.64 |
| ▸ | HTT | P42858 | 1/20 | 0.62 |
| ▸ | TSHR | P16473 | 3/20 | 0.61 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.61 |
| ▸ | TP53 | P04637 | 1/20 | 0.61 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetanilide SCHEMBL27909967 | 0.98 | NAPRT (0.91) | NAPRTHSD17B10MAPTKMT2ANPC1 | |
| SCHEMBL19669626 | 0.97 | NAPRT (1.00) | NAPRTHSD17B10MAPTKMT2ANPC1 | |
| Acetanilide SCHEMBL16922180 | 0.97 | NAPRT (1.00) | NAPRTHSD17B10MAPTKMT2ANPC1 | |
| Acetanilide SCHEMBL24681 | 0.97 | NAPRT (1.00) | NAPRTHSD17B10MAPTKMT2ANPC1 | |
| Acetanilide SCHEMBL3359084 | 0.97 | NAPRT (1.00) | NAPRTHSD17B10MAPTKMT2ANPC1 | |
| Acetanilide SCHEMBL1332076 | 0.97 | NAPRT (1.00) | NAPRTHSD17B10MAPTKMT2ANPC1 | |
| Acetanilide SCHEMBL8497808 | 0.95 | NAPRT (0.86) | NAPRTHSD17B10MAPTKMT2ANPC1 | |
| Acetanilide SCHEMBL11207565 | 0.95 | NAPRT (0.95) | NAPRTHSD17B10MAPTKMT2ANPC1 | |
| Acetanilide SCHEMBL11511638 | 0.95 | NAPRT (0.95) | NAPRTHSD17B10MAPTKMT2ANPC1 | |
| Acetanilide SCHEMBL3987435 | 0.95 | NAPRT (0.95) | NAPRTHSD17B10MAPTKMT2ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108147975-B | Continuous production method of m-aminoacetanilide hydrochloride | 浙江迪邦化工有限公司 | 2020-12-11 | — | — | CN | claimed |
| CN-101602697-A | 2-methoxyl group-5-methyl is right-beta-sulfuric ester ethyl sulfonyl aniline and preparation method thereof | CHAOZHONG HAN (CN) | 2009-12-16 | — | — | CN | claimed |
| CN-101602698-A | 2, the 5-dimethoxy is right-beta-sulfuric ester ethyl sulfonyl aniline and preparation method thereof | CHAOZHONG HAN (CN) | 2009-12-16 | — | — | CN | claimed |
| CN-101602699-A | O-methoxy is right-beta-sulfuric ester ethyl sulfonyl aniline and preparation method thereof | CHAOZHONG HAN (CN) | 2009-12-16 | — | — | CN | claimed |
| EP-1948164-A1 | PHARMACEUTICAL COMPOSITIONS OF MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES, LTD. (IN) | 2008-07-30 | — | — | EP | claimed |
| WO-2007045979-A1 | PHARMACEUTICAL COMPOSITIONS OF MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2007-04-26 | — | — | WO | claimed |
| EP-0358571-B1 | THIOFORMAMIDINES, THEIR PREPARATION AND MEDICAL APPLICATIONS | PIERRE FABRE MEDICAMENT (FR) | 1993-01-13 | — | — | EP | claimed |
| JP-4264078-A | — | — | None | — | — | JP | disclosed |
| US-12139461-B1 | Piperidine compounds as PDE5 inhibitors | KING SAUD UNIVERSITY (SA) | 2024-11-12 | — | — | US | disclosed |
| CN-117813334-A | Onium salt, blocking agent dissociation catalyst for blocking isocyanate, blocked isocyanate composition containing blocking agent dissociation catalyst, thermosetting resin composition, cured product, and method for producing same | 广荣化学株式会社 | 2024-04-02 | — | — | CN | disclosed |
| CN-111138311-B | Production method of m-aminoacetanilide | 烟台安诺其精细化工有限公司 | 2022-04-15 | — | — | CN | disclosed |
| CN-111072514-B | Preparation method of 3-acetamido-N, N-diacetoxyethylaniline | 烟台安诺其精细化工有限公司 | 2022-04-08 | — | — | CN | disclosed |
| CN-112358411-B | Process and device for continuously producing m-aminoacetanilide hydrochloride | 浙江迪邦化工有限公司 | 2021-08-17 | — | — | CN | disclosed |
| CN-101602697-A | 2-methoxyl group-5-methyl is right-beta-sulfuric ester ethyl sulfonyl aniline and preparation method thereof | CHAOZHONG HAN (CN) | 2009-12-16 | — | — | CN | disclosed |
| CN-101602699-A | O-methoxy is right-beta-sulfuric ester ethyl sulfonyl aniline and preparation method thereof | CHAOZHONG HAN (CN) | 2009-12-16 | — | — | CN | disclosed |
| CN-101367738-A | Preparation method of m-fluoroaniline | UNIV TIANJIN (CN) | 2009-02-18 | — | — | CN | disclosed |
| JP-H04264078-A | PRODUCTION OF PIPERAZINE DERIVATIVE | RICHTER GEDEON V G RT | 1992-09-18 | — | — | JP | disclosed |
| EP-0457243-A1 | Novel tricyclic compounds | SYNTEX (U.S.A.) INC. (US) | 1991-11-21 | — | — | EP | disclosed |
| EP-0456093-A2 | Biguanide derivatives and biocidal compositions containing them | H.B. FULLER LICENSING & FINANCING, INC. (US) | 1991-11-13 | — | — | EP | disclosed |
| EP-0045450-B1 | BENZOPHENONE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND MEDICAMENTS CONTAINING THEM | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1984-02-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12139461-B1 | Piperidine compounds as PDE5 inhibitors | PDE5A, PDE3A, PDE2A | GAA 969/4885CACNA1B 950/4885CA2 3683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.